China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight loss drug candidate, mazdutide (IBI362), after 48 weeks of treatment. The higher dose (9mg) of mazdutide demonstrated significant efficacy in achieving weight loss among Chinese subjects with obesity, alongside favorable safety profiles and multiple metabolic benefits.
Efficacy and Safety Data
The placebo-adjusted mean percentage change in body weight from baseline was -18.6% (-17.8 kg), positioning mazdutide on par with tirzepatide in terms of weight loss effect. This places Innovent’s drug candidate as a potential leader in the obesity treatment market, offering a promising alternative for patients seeking effective weight management solutions.
Licensing Agreement and Drug Mechanism
Innovent entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3, also known as mazdutide, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide not only promotes insulin secretion and lowers blood glucose but also increases energy expenditure and improves hepatic fat metabolism through the activation of the glucagon receptor.
Ongoing and Planned Clinical Studies
Currently, three pivotal Phase III studies are underway for mazdutide, in 4mg and 6mg dosages, targeting Chinese patients with overweight or obesity (GLORY-1) and type 2 diabetics (DREAMS-1 and DREAMS-2). Innovent plans to initiate a Phase III clinical study for mazdutide 9mg in Chinese patients with obesity by the end of 2023, further solidifying its commitment to advancing innovative treatments in metabolic health.
Conclusion
The Phase II data for Innovent Biologics’ mazdutide underscores the drug’s potential as a significant player in the weight loss and metabolic health space. With promising results and ongoing clinical trials, Innovent continues to pave the way for innovative solutions in obesity and diabetes management.-Fineline Info & Tech
